Ekso Bionics Holdings, Inc. (EKSO): Price and Financial Metrics


Ekso Bionics Holdings, Inc. (EKSO): $1.81

0.03 (+1.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EKSO Stock Summary

  • EKSO has a higher market value than only 6.71% of US stocks; more precisely, its current market capitalization is $36,428,678.
  • With a year-over-year growth in debt of -42.38%, Ekso Bionics Holdings Inc's debt growth rate surpasses only 9.5% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EKSO comes in at -106.27% -- higher than that of only 3.54% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Ekso Bionics Holdings Inc, a group of peers worth examining would be AWH, NVRO, STIM, TAOP, and IGC.
  • EKSO's SEC filings can be seen here. And to visit Ekso Bionics Holdings Inc's official web site, go to www.eksobionics.com.

EKSO Valuation Summary

  • EKSO's price/sales ratio is 6.5; this is 42.73% lower than that of the median Healthcare stock.
  • Over the past 90 months, EKSO's price/sales ratio has gone down 61.8.
  • EKSO's price/sales ratio has moved down 61.8 over the prior 90 months.

Below are key valuation metrics over time for EKSO.

Stock Date P/S P/B P/E EV/EBIT
EKSO 2021-08-31 6.5 1.5 -9.4 -2.7
EKSO 2021-08-30 6.3 1.5 -9.1 -2.4
EKSO 2021-08-27 6.4 1.5 -9.1 -2.5
EKSO 2021-08-26 6.3 1.5 -9.1 -2.4
EKSO 2021-08-25 6.3 1.4 -9.0 -2.3
EKSO 2021-08-24 6.2 1.4 -8.9 -2.2

EKSO Growth Metrics

    Its 5 year revenue growth rate is now at -23.86%.
  • Its 5 year net cashflow from operations growth rate is now at 41.98%.
  • Its 3 year price growth rate is now at -69%.
Over the past 15 months, EKSO's revenue has gone up $897,000.

The table below shows EKSO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 11.246 -11.156 -9.764
2021-09-30 9.424 -9.821 -10.877
2021-06-30 9.272 -8.616 -6.467
2021-03-31 9.325 -9.033 -16.961
2020-12-31 8.882 -8.755 -15.825
2020-09-30 10.349 -8.51 -14.57

EKSO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EKSO has a Quality Grade of D, ranking ahead of 7.97% of graded US stocks.
  • EKSO's asset turnover comes in at 0.242 -- ranking 100th of 104 Machinery stocks.
  • MOG.A, DRQ, and CECE are the stocks whose asset turnover ratios are most correlated with EKSO.

The table below shows EKSO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.242 0.615 -1.072
2021-03-31 0.303 0.608 -2.750
2020-12-31 0.426 0.571 -2.648
2020-09-30 0.489 0.538 -2.401
2020-06-30 0.529 0.511 -2.663
2020-03-31 0.556 0.493 -1.145

EKSO Price Target

For more insight on analysts targets of EKSO, see our EKSO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.00 Average Broker Recommendation 1.5 (Moderate Buy)

EKSO Stock Price Chart Interactive Chart >

Price chart for EKSO

EKSO Price/Volume Stats

Current price $1.81 52-week high $6.10
Prev. close $1.78 52-week low $1.54
Day low $1.77 Volume 34,600
Day high $1.85 Avg. volume 50,399
50-day MA $2.41 Dividend yield N/A
200-day MA $3.21 Market Cap 23.25M

Ekso Bionics Holdings, Inc. (EKSO) Company Bio


Founded in 2005 in Richmond, California, Ekso Bionics Holdings Inc employs approximately 92 people that design, develop, and sell wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets. The company’s first product, HULC was developed for the military in partnership with Lockheed Martin, enhancing soldier capabilities to allow them to carry heavier loads over further distances. The EksoNR is currently the only FDA-cleared exoskeleton for treatment of ABI, helping physical therapists, physiatrists, and doctors to clinically rehabilitate patients. The company’s CEO is Jack Peurach, who served as Executive Vice President, Products for SunPower Corp before becoming Ekso’s Chief Executive Officer.


EKSO Latest News Stream


Event/Time News Detail
Loading, please wait...

EKSO Latest Social Stream


Loading social stream, please wait...

View Full EKSO Social Stream

Latest EKSO News From Around the Web

Below are the latest news stories about Ekso Bionics Holdings Inc that investors may wish to consider to help them evaluate EKSO as an investment opportunity.

Ekso Bionics Holdings, Inc. (EKSO) CEO Steven Sherman on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 24, 2022

Ekso Bionics Holdings GAAP EPS of -$0.23, revenue of $4.1M

Ekso Bionics Holdings press release (EKSO): Q4 GAAP EPS of -$0.23.Revenue of $4.1M (+82.2% Y/Y).Cash on hand at December 31, 2021 was $40.4 million, compared to $12.9 million at…

Seeking Alpha | February 24, 2022

Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 8% and 1.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Ekso Bionics Reports Fourth Quarter and Year End 2021 Results

RICHMOND, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2021. Recent Highlights and Accomplishments Reported record revenue of $4.1 million in the fourth quarter of 2021Achieved gross margin of approximately 59% in the fourth quarter of 2021Booked a total of 30 EksoNR units in the f

Yahoo | February 24, 2022

Ekso Bionics to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

RICHMOND, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

GlobeNewswire | February 17, 2022

Read More 'EKSO' Stories Here

EKSO Price Returns

1-mo -26.12%
3-mo -29.57%
6-mo -47.38%
1-year -68.69%
3-year -91.68%
5-year -88.83%
YTD -31.70%
2021 -56.77%
2020 4.52%
2019 -68.47%
2018 -41.78%
2017 -46.48%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7011 seconds.